BR112021023607A2 - Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase - Google Patents
Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinaseInfo
- Publication number
- BR112021023607A2 BR112021023607A2 BR112021023607A BR112021023607A BR112021023607A2 BR 112021023607 A2 BR112021023607 A2 BR 112021023607A2 BR 112021023607 A BR112021023607 A BR 112021023607A BR 112021023607 A BR112021023607 A BR 112021023607A BR 112021023607 A2 BR112021023607 A2 BR 112021023607A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridine
- pyrazolo
- pyrrolo
- protein kinase
- kinase inhibitors
- Prior art date
Links
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical group C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title abstract 4
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical group C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase. a presente invenção refere-se a certos inibidores de btk, composições farmacêuticas dos mesmos e métodos de uso dos mesmos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962854983P | 2019-05-31 | 2019-05-31 | |
US201962904611P | 2019-09-23 | 2019-09-23 | |
US201962935091P | 2019-11-14 | 2019-11-14 | |
PCT/CN2020/093734 WO2020239124A1 (en) | 2019-05-31 | 2020-06-01 | SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021023607A2 true BR112021023607A2 (pt) | 2022-01-04 |
Family
ID=73553523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021023607A BR112021023607A2 (pt) | 2019-05-31 | 2020-06-01 | Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220235049A1 (pt) |
EP (1) | EP3976607A4 (pt) |
JP (1) | JP2022534715A (pt) |
KR (1) | KR20220016090A (pt) |
CN (1) | CN114008042B (pt) |
AU (1) | AU2020283597A1 (pt) |
BR (1) | BR112021023607A2 (pt) |
CA (1) | CA3137985A1 (pt) |
MX (1) | MX2021014674A (pt) |
WO (1) | WO2020239124A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230110286A (ko) * | 2020-11-17 | 2023-07-21 | 포천 바이오사이언시스, 리미티드 | 단백질 키나제 억제제로서 치환된 피롤로 [2,3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체 |
EP4234558A1 (en) * | 2020-12-07 | 2023-08-30 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | Pyrrolopyridine compound and application thereof |
CN112574200B (zh) * | 2021-02-26 | 2021-06-11 | 安润医药科技(苏州)有限公司 | Btk和/或btk的突变体c481s的小分子抑制剂 |
CN115028633B (zh) * | 2021-03-08 | 2023-12-22 | 药雅科技(上海)有限公司 | 吡咯并嘧啶类化合物的制备及其应用 |
CN113979891A (zh) * | 2021-11-08 | 2022-01-28 | 上海高准医药有限公司 | 一种克立硼罗及其中间产物的制备方法 |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
CN114409654A (zh) * | 2021-12-30 | 2022-04-29 | 安徽普利药业有限公司 | 一种btk抑制剂的中间体合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1696920E (pt) * | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
MY153898A (en) * | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AU2010321883A1 (en) * | 2009-11-18 | 2012-05-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112015028845A2 (pt) * | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
WO2018039310A1 (en) * | 2016-08-24 | 2018-03-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
EP3823968A1 (en) * | 2018-07-16 | 2021-05-26 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN112608318B (zh) * | 2019-12-16 | 2023-09-08 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其用途 |
-
2020
- 2020-06-01 WO PCT/CN2020/093734 patent/WO2020239124A1/en unknown
- 2020-06-01 BR BR112021023607A patent/BR112021023607A2/pt unknown
- 2020-06-01 MX MX2021014674A patent/MX2021014674A/es unknown
- 2020-06-01 AU AU2020283597A patent/AU2020283597A1/en active Pending
- 2020-06-01 JP JP2021570188A patent/JP2022534715A/ja active Pending
- 2020-06-01 US US17/615,420 patent/US20220235049A1/en active Pending
- 2020-06-01 EP EP20814173.9A patent/EP3976607A4/en active Pending
- 2020-06-01 KR KR1020217039485A patent/KR20220016090A/ko unknown
- 2020-06-01 CA CA3137985A patent/CA3137985A1/en active Pending
- 2020-06-01 CN CN202080040076.0A patent/CN114008042B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
EP3976607A1 (en) | 2022-04-06 |
KR20220016090A (ko) | 2022-02-08 |
CN114008042A (zh) | 2022-02-01 |
MX2021014674A (es) | 2022-01-11 |
AU2020283597A1 (en) | 2021-11-25 |
CA3137985A1 (en) | 2020-12-03 |
US20220235049A1 (en) | 2022-07-28 |
EP3976607A4 (en) | 2023-07-19 |
WO2020239124A1 (en) | 2020-12-03 |
CN114008042B (zh) | 2023-10-03 |
JP2022534715A (ja) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021023607A2 (pt) | Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase | |
EA201791692A1 (ru) | 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ | |
EA201990048A1 (ru) | [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ | |
WO2017108723A3 (en) | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | |
CY1119588T1 (el) | Εκλεκτικοι αναστολεις pi3κ δελτα | |
EA201400701A1 (ru) | Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk) | |
CL2015002303A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
BR112016024626A8 (pt) | compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet | |
UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
PH12015502459A1 (en) | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | |
BR112018072168A2 (pt) | compostos derivados da pirimidina como inibidores da quinase jak | |
BR112017023038A2 (pt) | imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa | |
DOP2018000266A (es) | 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1 | |
CO2021014022A2 (es) | Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
BR112017026278A2 (pt) | 1,5-di-hidro-4h-pirazolo[3,4-d]pirimidin-4-onas e 1,5-di-hidro-4h-pirazolo[4,3-c]piridin-4-onas como inibidores de pde1 | |
UY37559A (es) | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton | |
CL2019001669A1 (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1. | |
CY1109891T1 (el) | Παραγωγα ν-(αρυλαλκυλ)-1η-πυρρολοπυριδιν-2-καρβοξαμιδιων, η παρασκευη τους και η εφαρμογη τους σε θεραπειες | |
MX2020009586A (es) | Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk. | |
EA201691934A1 (ru) | Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1 | |
DK3840832T3 (da) | Imidazo[1,2-b]pyridaziner som trk-inhibitorer | |
MX367772B (es) | Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk. | |
UA117318C2 (uk) | ПОХІДНІ 7-(МОРФОЛІНІЛ)-2-(N-ПІПЕРАЗИНІЛ)МЕТИЛТІЄНО[2,3-с]ПІРИДИНУ ЯК ПРОТИРАКОВІ ЛІКУВАЛЬНІ ЗАСОБИ | |
BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON PHARMACEUTICALS, LTD. (CN) |
|
B25H | Request for change of headquarter rejected |
Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON PHARMACEUTICALS, LTD. (CN) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870240005936 DE23/01/2024, EM VIRTUDE DA SOLICITACAO JA TER SIDO ATENDIDA PELA PETICAO 870230082563 DE18/09/2023. |
|
B25A | Requested transfer of rights approved |
Owner name: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) ; FOCHON BIOSCIENCES, LTD. (CN) |
|
B25A | Requested transfer of rights approved |
Owner name: FOCHON BIOSCIENCES, LTD. (CN) |